Rebecsinib, an RNA Splicing and Base Editing Inhibitor to Target Cancer Stem Cells in Refractory Myeloid Malignancies

Return to Grants

Grant Award Details

Grant Type:

Clinical Trial Stage Projects

Grant Number:

CLIN2-20409

Investigator(s):

Name:

Curtis Scribner

Institution:

Aspera Biomedicines, Inc

Type:

PI

Disease Focus:

Blood Cancer, Cancer, Leukemia, Acute Myeloid (AML)

Award Value:

$5,516,253

Status:

Pre-Active

Grant Application Details

Application Title:

Rebecsinib, an RNA Splicing and Base Editing Inhibitor to Target Cancer Stem Cells in Refractory Myeloid Malignancies